Addex Therapeutics Stock Today
| ADXN Stock | USD 5.78 0.23 4.14% |
|
|
Addex Therapeutics is selling at 5.78 as of the 4th of December 2023; that is 4.14% increase since the beginning of the trading day. The stock's open price was 5.55. Addex Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Addex Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of September 2023 and ending today, the 4th of December 2023. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of January 2020 | Category Healthcare | Classification Health Care |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. The company has 992.28 K outstanding shares of which 5.55 K shares are presently shorted by private and institutional investors with about 0.64 trading days to cover. More on Addex Therapeutics
Moving together with Addex Stock
| + | 0.87 | ERNA | Eterna Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.76 | JNJ | Johnson Johnson | Aggressive Push | PairCorr | |
| + | 0.72 | MRK | Merck Company | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.88 | PFE | Pfizer Inc | Downward Rally | PairCorr |
Moving against Addex Stock
| - | 0.9 | BTC | BTC Health Limited | PairCorr | ||
| - | 0.74 | TCRX | Tscan Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.7 | METROPOLIS | Metropolis Healthcare | PairCorr | ||
| - | 0.68 | MMSI | Merit Medical Systems | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.56 | SNDA | Sonida Senior Living | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.46 | ONCT | Oncternal Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.44 | OPTI | OptiBiotix Health Plc | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 4th of April 2024
Addex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Addex Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Addex Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| SEC Filings | Addex Therapeutics Security & Exchange Commission EDGAR Reports | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Addex Therapeutics report their recommendations after researching Addex Therapeutics' financial statements, talking to executives and customers, or listening in on Addex Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Addex Therapeutics. The Addex consensus assessment is calculated by taking the average forecast from all of the analysts covering Addex Therapeutics. Hold1 Opinion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Piotroski F Score Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Addex Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Addex Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks. FrailDetails
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Macroaxis Advice The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Addex Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details Strong SellFairly Valued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Addex Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Addex Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Addex Therapeutics' financial leverage. It provides some insight into what part of Addex Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Addex Therapeutics (ADXN) is traded on NASDAQ Exchange in USA. It is located in Chemin des Mines, 9, Geneva, Switzerland, 1202 and employs 24 people. Addex Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Addex Therapeutics's market, we take the total number of its shares issued and multiply it by Addex Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Addex Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 992.28 K outstanding shares of which 5.55 K shares are presently shorted by private and institutional investors with about 0.64 trading days to cover.
Addex Therapeutics currently holds about 8.81 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Check Addex Therapeutics Probability Of Bankruptcy
Ownership30% of Addex Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change.
Ownership Allocation
Check Addex Ownership DetailsAddex Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Addex Therapeutics jumping above the current price in 90 days from now is about 85.69%. The Addex Therapeutics probability density function shows the probability of Addex Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0626. This suggests Addex Therapeutics market returns are highly reactive to returns on the market. As the market goes up or down, Addex Therapeutics is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Addex Therapeutics is significantly underperforming NYSE Composite.
Based on a normal probability distribution, the odds of Addex Therapeutics to move above the current price in 90 days from now is about 85.69 (This Addex Therapeutics probability density function shows the probability of Addex Stock to fall within a particular range of prices over 90 days) .
Addex Therapeutics Historical Income Statement
Addex Therapeutics Income Statement is one of the three primary financial statements used for reporting Addex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Addex Therapeutics revenue and expense. Addex Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Addex Therapeutics' Gross Profit is very stable as compared to the past year. As of the 4th of December 2023, Revenues is likely to grow to about 2.1 M, while Consolidated Income is likely to drop (21.4 M). View More FundamentalsAddex Stock Against Markets
Picking the right benchmark for Addex Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Addex Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Addex Therapeutics is critical whether you are bullish or bearish towards Addex Therapeutics at a given time. Please also check how Addex Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Addex Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Addex Therapeutics Corporate Management
Elected by the shareholders, the Addex Therapeutics' board of directors comprises two types of representatives: Addex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Addex. The board's role is to monitor Addex Therapeutics' management team and ensure that shareholders' interests are well served. Addex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Addex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Dyer | CEO CoFounder | Profile | |
| Werner Henrichi | Consultant | Profile | |
| Mikhail Kalinichev | Head Science | Profile | |
| JeanPhilippe Rocher | Head Chemistry | Profile | |
| Roger MD | Chief Director | Profile | |
| Lnaic Teyssdou | Head Fin | Profile | |
| Robert Lutjens | Head Biology | Profile |
How to buy Addex Stock?
Before investing in Addex Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Addex Therapeutics. To buy Addex Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Addex Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Addex Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Addex Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Addex Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Addex Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Addex Stock please use our How to Invest in Addex Therapeutics guide.
Already Invested in Addex Therapeutics?
The danger of trading Addex Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Addex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Addex Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Addex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in national income and product accounts. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Addex Stock analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.58) | Revenue Per Share 3.72 | Quarterly Revenue Growth (0.21) | Return On Assets (0.75) | Return On Equity (1.91) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.